AstraZeneca Plc After The Patent Cliff

AstraZeneca plc (LON:AZN) is set to recover strongly according to one Fool.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The thing about technological and scientific change is that it can happen very quickly. University start-ups can be transformed into global titans  — think of Facebook. And internationally known giants can end up in the bankruptcy courts — think of Kodak.

The pace of change in the pharmaceutical industry is almost as fast as in the computer industry. Just think of recent innovations: biotechnology and biologics that provides many of today’s new medicines; stem cells that will soon mean you will be able to grow your own organs and body parts; gene sequencing that will soon be so cheap that it will be part of normal day-to-day medical screening, as well as novel diagnostics and vaccine technologies.

As the worlds of computing and medicine collide, if anything this scientific revolution is accelerating, not slowing down.

Our first picture of the pharma industry post the patent cliff

In the 1980s and 1990s, the pharmaceutical industry was booming as drug after drug was launched. This was the rapid growth phase of the pharmaceutical industry, when companies such as GlaxoSmithKline and AstraZeneca (LSE: AZN) (NYSE: GSK.US) bought up companies and expanded their R&D facilities.

But the past decade has been a decade dominated by the pharmaceutical patent cliff. This is the idea that many of the industry’s main blockbuster drugs are nearing patent expiry. The question was how the pharmaceutical industry would adapt to a world where drug profits are falling rather than rising.

Now, for the first time, we are beginning to form a picture of Big Pharma post the patent cliff.

Of all the drugs companies, AstraZeneca was seen as the company that had the steepest patent cliff to negotiate. With the expiry of patents on multi-billion pound drugs such as Seroquel and Nexium, AZ’s profits have tumbled. Here are the simple numbers:

2011 EPS: 470p, 2012: 306p, 2013: 257p, 2014: 262p, 2015: 246p

In a few short years, AstraZeneca’s earnings per share has halved. The company’s P/E has thus increased from single digits to 14 in the current year and 15 next year — higher than the FTSE 100 average. The picture we have is of a company whose profits have fallen sharply, and is no longer the bargain it seemed a few years ago.

Restructuring, refreshing and recovering

AstraZeneca’s chief executive summarises the situation succinctly. The company is at the early stages of a long journey to recovery.

The goal in 2014 is to invest in research and acquisitions to rebuild the firm’s drugs pipeline. AstraZeneca is restructuring and refreshing its research centres and will reduce its global workforce by 10%. By 2017 the business aims to see a return to growth and to have restored its revenues to its 2013 level. By 2020 the company aims to have launched 10 blockbuster drugs since 2013. After 2020 the company should have achieved leadership in its core technical areas.

These goals are ambitious, but the fact that the company’s share price has increased by 30% in the past year shows the market’s confidence that AstraZeneca is now firmly on the path to recovery, and is past the worst of the patent cliff. I rate the shares a hold.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat owns shares in none of the companies mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

2 mouthwatering FTSE growth stocks I’d buy and hold for 10 years

Growth stocks purchased today could be the gateway to many years of capital growth and returns. Here are two picks…

Read more »

Investing Articles

Can the IAG share price really be as dirt cheap as it looks?

While most shares have recovered since the Covid days, the IAG share price is staying stuck to rock bottom. Surely…

Read more »

Investing Articles

BAE Systems shares are flying! Have I missed the boat?

Sumayya Mansoor looks into whether or not BAE Systems shares are still a good buy for her portfolio after the…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

1 heavyweight FTSE 100 share I’d buy as London retakes its crown

Some Footsie firms are extremely large, but that doesn't mean they couldn't get even bigger. Here's one such FTSE 100…

Read more »

Investing Articles

I’d buy 5,127 National Grid shares to generate £250 of monthly passive income

With a dividend yield of 6.5%, Muhammad Cheema takes a look at how National Grid shares can generate a healthy…

Read more »

Investing Articles

The FTSE 100’s newest member looks like a no-brainer to me!

This Fool explains why she sees the newest member of the FTSE 100 as a great opportunity after its recent…

Read more »

Investing Articles

Empty Stocks and Shares ISA? Here’s how I’d start earning a second income from scratch

Like the thought of earning extra cash tax free? Our writer explains what he'd do to begin earning passive income…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

No savings at 25? I’d start by investing £3k in these 3 red-hot FTSE 100 shares

Harvey Jones thinks these three FTSE 100 stocks would be a great way to kickstart a portfolio of UK shares.…

Read more »